Estimates of HIV transmitted drug resistance can be inflated due to natural sequence polymorphisms

Journal of Acquired Immune Deficiency Syndromes

Volumn 58, Issue 5, 2011, Pages

  Frentz, Dineke ^a   Van De Vijver, David A M C ^a   Boucher, Charles A B ^a   Albert, Jan ^b,c  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; NUCLEOTIDYLTRANSFERASE INHIBITOR; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE;

AMINO ACID SUBSTITUTION; ANTIVIRAL RESISTANCE; CYTOTOXIC T LYMPHOCYTE; DNA POLYMORPHISM; GENE MUTATION; GENOTYPE; HIV TRANSMITTED DRUG RESISTANCE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; LETTER; MONTE CARLO METHOD; PATIENT DECISION MAKING; PREDICTIVE VALUE; PRIORITY JOURNAL; VIRUS GENOME; VIRUS REPLICATION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; HIV; HIV INFECTIONS; HUMANS; POLYMORPHISM, GENETIC; WORLD HEALTH ORGANIZATION;

EID: 81755188373     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e3182364c80     Document Type: Letter

References (18)

1. Wittkop L, Gunthard HF, de Wolf F, et al. Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis. 2011;11:363-371.
2. Wensing AM, Boucher CA. Worldwide transmission of drug-resistant HIV. AIDS Rev. 2003;5:140-155. (Pubitemid 37336631)
3. Geretti AM. Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis. 2007;20:22-32. (Pubitemid 46052123)
4. Van de Vijver D, Wensing A, Boucher C. The epidemiology of transmission of drugs resistant HIV-1. In: HIV Sequence Compendium 2006/2007 (Leitner T, et al., eds.). Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2007, pp, 17-36.
5. Bennett DE, Camacho RJ, Otelea D, et al. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One. 2009;4:e4724.
6. Bennett DE, Myatt M, Bertagnolio S, et al. Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther. 2008;13(suppl 2):25-36. (Pubitemid 352019087)
7. Vercauteren J, Wensing AM, van de Vijver DA, et al. Transmission of drug-resistant HIV-1 is stabilizing in Europe. J Infect Dis. 2009;200:1503-1508.
8. Wheeler WH, Ziebell RA, Zabina H, et al. Prevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, U.S.-2006. AIDS. 2010 1203-1212.
9. Metzner KJ, Rauch P, von Wyl V, et al. Efficient suppression of minority drug-resistant HIV type 1 (HIV-1) variants present at primary HIV-1 infection by ritonavir-boosted protease inhibitor-containing antiretroviral therapy. J Infect Dis. 2010;201:1063-1071.
10. Bracciale L, Colafigli M, Zazzi M, et al. Prevalence of transmitted HIV-1 drug resistance in HIV-1-infected patients in Italy: evolution over 12 years and predictors. J Antimicrob Chemother. 2009;64:607-615.
11. Bartmeyer B, Kuecherer C, Houareau C, et al. Prevalence of transmitted drug resistance and impact of transmitted resistance on treatment success in the German HIV-1 seroconverter cohort. PLoS One. 2010;5:e12718.
12. Werb D, Mills EJ, Montaner JS, et al. Risk of resistance to highly active antiretroviral therapy among HIV-positive injecting drug users: a meta-analysis. Lancet Infect Dis. 2010;10:464-469.
13. Ndembi N, Hamers RL, Sigaloff KC, et al. Transmitted antiretroviral drug resistance among newly HIV-1 diagnosed young individuals in Kampala. AIDS. 25:905-910.
14. Hamers RL, Derdelinckx I, van Vugt M, et al. The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther. 2008;13:625-639.
15. Myatt M, Bennett DE. A novel sequential sampling technique for the surveillance of transmitted HIV drug resistance by crosssectional survey for use in low resource settings. Antivir Ther. 2008;13(suppl 2): 37-48. (Pubitemid 352019088)
16. Mueller SM, Schaetz B, Eismann K, et al. Dual selection pressure by drugs and HLA class I-restricted immune responses on human immunodeficiency virus type 1 protease. J Virol. 2007;81:2887-2898. (Pubitemid 46447052)
17. Schuurman R, Brambilla D, de Groot T, et al. Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program. AIDS Res Hum Retroviruses. 2002;18:243-248. (Pubitemid 34253141)
18. Li JZ, Paredes R, Ribaudo HJ, et al. Low-frequency HIV-1 drug resistance mutations and risk of NNRTI-based antiretroviral treatment failure: a systematic review and pooled analysis. JAMA. 2011;305: 1327-1335.